Sonoma Pharmaceuticals Inc (SNOA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sonoma Pharmaceuticals Inc (SNOA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11476
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for advanced wound management, nursing home and home healthcare, wound and skin care, among others. It offers women’s healthcare products, Microcyn skin and wound care products, Regenacyn advanced scar management hydrogel and animal healthcare, among others. Sonoma develops its products based on shelf-stable microcyn technology platform. The company sells its products through OTC stores. The company operates in the Netherlands and the US. Sonoma is headquartered in Petaluma, California, the US.

Sonoma Pharmaceuticals Inc (SNOA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Licensing Agreements 13
Brill Pharma Enters into Licensing Agreement with Sonoma Pharma 13
U.SK Dermatology Enters into Licensing Agreement with Sonoma Pharma 14
Oculus Innovative Amends the Licensing Agreement With Ruthigen 15
AmDerma Pharma Exercises its Option Licensing Agreement With Oculus Innovative Sciences 17
Oculus Innovative Sciences Enters Into Licensing Agreement With More Pharma 18
Equity Offering 19
Sonoma Pharma Prices Public Offering of Units 19
Sonoma Pharma Raises USD5 Million in Public Offering of Shares 20
Oculus Innovative Sciences Raises USD3.26 million in Public Offering Of Shares 22
Oculus Innovative Sciences Raises USD3.4 Million in Public Offering of Units 23
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 24
Oculus Innovative Sciences Raises USD6.3 Million in Public Offering of Shares and Warrants 25
Oculus Innovative Sciences Raises USD1.35 Million in Private Placement Of Units 27
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2.2 Million 28
Oculus Innovative Sciences Completes Public Offering Of Common Stock For US$3.5 Million 29
Oculus Innovative Sciences Completes Private Placement Of Preferred Stock For US$1 Million 30
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2 Million 31
Asset Transactions 32
Invekra Acquires Latin America Business of Sonoma Pharma for USD22 Million 32
Sonoma Pharmaceuticals Inc – Key Competitors 33
Sonoma Pharmaceuticals Inc – Key Employees 34
Sonoma Pharmaceuticals Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Business Unit 36
Recent Developments 37
Financial Announcements 37
Nov 08, 2018: Sonoma Pharmaceuticals reports record revenue in second quarter FY 2019 37
Aug 08, 2018: Sonoma Pharmaceuticals reports first quarter fy 2019 financial results 39
Jun 13, 2018: Sonoma Pharmaceuticals Announces Fiscal Year And Fourth Quarter 2018 Financial Results 40
Feb 07, 2018: Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% 42
Nov 09, 2017: Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million 44
Aug 08, 2017: Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 46
Feb 09, 2017: Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 47
Corporate Communications 49
Sep 19, 2018: Sonoma Pharmaceuticals names Phillipe Weigerstorfer as Board Director 49
May 08, 2018: Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer 50
Jan 31, 2017: Sonoma Pharmaceuticals Appoints Marc Umscheid As Chief Strategy And Marketing Officer 51
Other Significant Developments 52
Aug 28, 2018: Sonoma Pharmaceuticals announces results from study of sonoma’s performance-stabilized HOCl (hypochlorous acid) in management of acne vulgaris 52
Jul 13, 2017: Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sonoma Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Brill Pharma Enters into Licensing Agreement with Sonoma Pharma 13
U.SK Dermatology Enters into Licensing Agreement with Sonoma Pharma 14
Oculus Innovative Amends the Licensing Agreement With Ruthigen 15
AmDerma Pharma Exercises its Option Licensing Agreement With Oculus Innovative Sciences 17
Oculus Innovative Sciences Enters Into Licensing Agreement With More Pharma 18
Sonoma Pharma Prices Public Offering of Units 19
Sonoma Pharma Raises USD5 Million in Public Offering of Shares 20
Oculus Innovative Sciences Raises USD3.26 million in Public Offering Of Shares 22
Oculus Innovative Sciences Raises USD3.4 Million in Public Offering of Units 23
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 24
Oculus Innovative Sciences Raises USD6.3 Million in Public Offering of Shares and Warrants 25
Oculus Innovative Sciences Raises USD1.35 Million in Private Placement Of Units 27
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2.2 Million 28
Oculus Innovative Sciences Completes Public Offering Of Common Stock For US$3.5 Million 29
Oculus Innovative Sciences Completes Private Placement Of Preferred Stock For US$1 Million 30
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2 Million 31
Invekra Acquires Latin America Business of Sonoma Pharma for USD22 Million 32
Sonoma Pharmaceuticals Inc, Key Competitors 33
Sonoma Pharmaceuticals Inc, Key Employees 34
Sonoma Pharmaceuticals Inc, Other Locations 35
Sonoma Pharmaceuticals Inc, Subsidiaries 35
Sonoma Pharmaceuticals Inc, Business Unit 36

List of Figures
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Sonoma Pharmaceuticals Inc (SNOA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Telia Company AB:企業の戦略・SWOT・財務情報
    Telia Company AB - Strategy, SWOT and Corporate Finance Report Summary Telia Company AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SIGA Technologies Inc (SIGA):企業の財務・戦略的SWOT分析
    Summary Siga Technologies Inc (Siga) a subsidiary of MacAndrews and Forbes Holdings Inc, is a health security service provider. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. Siga offers product su …
  • Gr. Sarantis S.A. (SAR):企業の財務・戦略的SWOT分析
    Gr. Sarantis S.A. (SAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Malayan Flour Mills Berhad:戦略・SWOT・企業財務分析
    Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report Summary Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Dentsply Sirona Inc (XRAY):企業の財務・戦略的SWOT分析
    Dentsply Sirona Inc (XRAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • F5 Networks, Inc. (FFIV):企業の財務・戦略的SWOT分析
    F5 Networks, Inc. (FFIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Caribbean Utilities Company, Ltd.:発電所・企業SWOT分析
    Caribbean Utilities Company, Ltd. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • ABB Ltd (ABBN):石油・ガス:M&Aディール及び事業提携情報
    Summary ABB Ltd (ABB) is a provider of industrial technologies. It offers products, systems, solutions, and services in electrification products, motion, industrial automation, industrial automation, and power grids. The company’s offerings harness power reliability, increase industrial productivity …
  • Gentag Inc-医療機器分野:企業M&A・提携分析
    Summary Gentag Inc (Gentag) is a medical device company that patent and develops wireless sensor technology products. The company provides wireless products to personal health and diagnostics. It offers wireless sensor network services. Gentag’s products comprise medication and packaging sensor, imm …
  • Clean Harbors Inc (CLH):石油・ガス:M&Aディール及び事業提携情報
    Summary Clean Harbors Inc (Clean Harbors) is a provider of environmental, industrial and energy services. The company offers waste disposal and recycling, emergency response, chemical packing, field services, production services, exploration services, directional boring, lodging services and onsite …
  • Colas SA (RE):企業の財務・戦略的SWOT分析
    Colas SA (RE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Fluor Corporation (FLR)-エネルギー分野:企業M&A・提携分析
    Summary Fluor Corporation (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other ser …
  • KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報
    Summary KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries …
  • Mmi Holdings Ltd.
    Mmi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mmi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • DIA Imaging Analysis Ltd-医療機器分野:企業M&A・提携分析
    Summary DIA Imaging Analysis Ltd (DIA Imaging Analysis), formerly DiACardio Ltd is a healthcare technology company that offers medical imaging analysis software solutions. The company’s products comprise LVivo SWM, LVivo EF, and LVivo Strain. DiACardio’s LVivo SWM is a fully automated echo device or …
  • Turisthotel d.d.:企業の戦略・SWOT・財務情報
    Turisthotel d.d. - Strategy, SWOT and Corporate Finance Report Summary Turisthotel d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Mckinsey & Company, Inc.:企業の戦略・SWOT・財務分析
    Mckinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mckinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Heidelberger Druckmaschinen AG (HDD):企業の財務・戦略的SWOT分析
    Heidelberger Druckmaschinen AG (HDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • CAE Inc.:企業の戦略・SWOT・財務情報
    CAE Inc. - Strategy, SWOT and Corporate Finance Report Summary CAE Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Imdex Ltd (IMD):企業の財務・戦略的SWOT分析
    Imdex Ltd (IMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆